Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EMN 2018 | Managing plasma cell leukemia: Pls, IMiDs, alkylating agents and antibodies

Torben Plesner • 4 May 2018
EMN 2018
Multiple Myeloma Antibodies Carfilzomib Daratumumab Lenalidomide Pomalidomide

The incorporation of novel biological agents has become the cornerstone of treatment in multiple myeloma (MM). In this video, Torben Plesner, MD, from the University of Southern Denmark, Vejle, Denmark, discusses the variety of agents used in the therapeutic management of MM. This interview was recorded at the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy.

More from Torben Plesner

4:43
Mechanistic insights into the resistance to anti-CD38 therapy
Torben Plesner • 14 Sep 2019
3:36
Daratumumab practical considerations in MM
Torben Plesner • 16 May 2019
2:08
Novel drug delivery method to prevent daratumumab infusion-related reactions in MM
Torben Plesner • 19 Jul 2018
3:10
The challenges of treating plasma cell leukemia
Torben Plesner • 4 May 2018

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals